Evidence map›Paper›PMID 35163506›Full record

ArticleInternational journal of molecular sciences2022

Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.

Chi-Cheng Huang, Chih-Yi Liu, Chi-Jung Huang, Yao-Chun Hsu, Heng-Hui Lien, Jia-Uei Wong, Feng-Chuan Tai, Wen-Hui Ku, Chi-Feng Hung, Jaw-Town Lin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Chi-Cheng HuangDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan.ORCID 0000-0003-4378-4776
Chih-Yi LiuDepartment of Pathology, Cathay General Hospital SiJhih, New Taipei 221, Taiwan.ORCID 0000-0002-3996-8452
Chi-Jung HuangDepartment of Medical Research, Cathay General Hospital, Taipei 106, Taiwan.
Yao-Chun HsuDivision of Gastroenterology, Department of Internal Medicine, E-da Hospital, Kaohsiung 82445, Taiwan.
Heng-Hui LienDivision of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan.
Jia-Uei WongDivision of General Surgery, Department of Surgery, Fu-Jen Catholic University Hospital, New Taipei 243, Taiwan.
Feng-Chuan TaiDivision of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan.
Wen-Hui KuDepartment of Clinical Pathology and Molecular Medicine, Taipei Institute of Pathology, Taipei 10374, Taiwan.
Chi-Feng HungSchool of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei 242, Taiwan.ORCID 0000-0003-3478-5451
Jaw-Town LinDigestive Medicine Center, China Medical University Hospital, Taichung 404, Taiwan.
Ching-Shui HuangDivision of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan.
Han-Sun ChiangSchool of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei 242, Taiwan.
Fu Jen Catholic University · TWNational Taiwan University · TWCathay General Hospital · TWChina Medical University · TW

Funding

Ministry of Science and Technology, R.O.C. MOST106-2632-B-030-001
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PAC) is the 8th leading cause of cancer-related deaths in Taiwan, and its incidence is increasing. The development of PAC involves successive accumulation of multiple genetic alterations. Understanding the molecular pathogenesis and heterogeneity of PAC may facilitate personalized treatment for PAC and identify therapeutic agents. We performed tumor-only next-generation sequencing (NGS) with targeted panels to explore the molecular changes underlying PAC patients in Taiwan. The Ion Torrent Oncomine Comprehensive Panel (OCP) was used for PAC metastatic lesions, and more PAC samples were sequenced with the Ion AmpliSeq Cancer Hot Spot (CHP) v2 panel. Five formalin-fixed paraffin-embedded (FFPE) metastatic PAC specimens were successfully assayed with OCP, and

Indexed as

MutationAdenocarcinomaAsian PeopleHigh-Throughput Nucleotide SequencingHumansNeoplasm MetastasisPancreatic NeoplasmsProspective StudiesProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 2Receptor, Platelet-Derived Growth Factor alphaRetrospective StudiesSequence Analysis, DNATaiwanTumor Suppressor Protein p53FGFR2 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 2Receptor, Platelet-Derived Growth Factor alphaTP53 protein, humanTumor Suppressor Protein p53actionable mutationnext-generation sequencingpancreatic adenocarcinomaTaiwantargeted sequencing

Identifiers

PMID35163506
PMCPMC8835797
OpenAlexW4210611384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.